 |
70 Diseases |  |
129 Trials |
|
129 Trials |  |
8945 News |  |
| «12...89101112131415161718...120121» |
- Rinvoq (upadacitinib) / AbbVie
UPADACITINIB IS EFFECTIVE AND SAFE FOR THE TREATMENT OF ULCERATIVE COLITIS AND CROHN'S DISEASE: 1-YEAR PROSPECTIVE REAL-WORLD EXPERIENCE (Hall A, Poster Hall - Walter E. Washington Convention Center) - Mar 14, 2024 - Abstract #DDW2024DDW_5346;
Background : Upadacitinib (UPA) is a novel selective Janus kinase 1 inhibitor that has shown efficacy and received approval for the treatment of moderate-to-severe ulcerative colitis (UC) and Crohn's disease (CD). In this large 1-year real-world experience in medically resistant patients with UC or CD, we report that UPA is both effective and safe, including in those who had prior exposure to tofacitinib.
- RATES OF ESCALATION TO ADVANCED THERAPY IN PATIENTS WITH ULCERATIVE PROCTITIS AT SIX MONTHS, ONE YEAR, AND TWO YEARS POST DIAGNOSIS (Hall A, Poster Hall - Walter E. Washington Convention Center) - Mar 14, 2024 - Abstract #DDW2024DDW_5339;
We excluded those on prior advanced therapy (azathioprine, methotrexate, mercaptopurine, infliximab, golimumab, adalimumab, vedolizumab, tofacitinib, upadacitinib, ustekinumab, ozanimod)...Anti-TNFs were the most used medication class, with infliximab or adalimumab being the most frequently used agents. Our data suggests a mostly benign disease course in patients with UP with a low percentage requiring advanced therapies.
- Stelara (ustekinumab) / J&J, Entyvio (vedolizumab) / Takeda
SYSTEMATIC REVIEW WITH META-ANALYSIS: SAFETY AND EFFICTIVENESS OF COMBINING BIOLOGICS AND SMALL MOLECULES IN INFLMAMMATORY BOWEL DISEASE (Hall A, Poster Hall - Walter E. Washington Convention Center) - Mar 14, 2024 - Abstract #DDW2024DDW_5329;
Of these 264 (49.7%) were men. Data from 23 studies revealed median prior usage of 2-4 biologics in 16 studies.
- ANTI TNF MEDICATIONS BUT NOT JAK INHIBITORS ARE ASSOCIATED WITH INCREASED RISK OF VENOUS THROMBOEMBOLISM. DATA FROM A LARGE NATIONAL COHORT. IS IT THE MECHANISM OF THE DRUG OR THE DISEASE? (Hall A, Poster Hall - Walter E. Washington Convention Center) - Mar 14, 2024 - Abstract #DDW2024DDW_5303;
Data from 23 studies revealed median prior usage of 2-4 biologics in 16 studies. We compared patients on various IBD therapies [non-advanced (prednisone, budesonide, 5-aminosalicylates), immunomodulators (IM), anti-TNF (infliximab, adalimumab, certolizumab, golimumab), anti-integrin (vedolizumab), anti-IL12/23 (ustekinumab, rizankinumab), JAK inhibitors (tofacitinib, upadacitinib)], and statins for outcomes of VTE
- COMPARATIVE EFFICACY OF BIOLOGICS AND SMALL MOLECULE THERAPIES IN IMPROVING HEALTH RELATED QUALITY OF LIFE IN ULCERATIVE COLITIS; SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS. (Hall A, Poster Hall - Walter E. Washington Convention Center) - Mar 14, 2024 - Abstract #DDW2024DDW_4911;
All medications were superior to placebo except etrolizumab (OR= 0.87 [95% CI 0.39; 1.92]) Per SUCRA score, tofacitinib ranked highest (88%), followed by golimumab (77%)...In addition, guselkumab ranked highest followed by tofacitinib and upadacitinib in improving HRQoL. During maintenance of remission, Tofacitinib ranked highest.
- EFFICACY AND SAFETY OF ADVANCED MEDICAL TREATMENTS FOR MAINTENANCE OF REMISSION IN CROHN'S DISEASE: A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS (Hall A, Poster Hall - Walter E. Washington Convention Center) - Mar 14, 2024 - Abstract #DDW2024DDW_4910;
Tofacitinib was not effective and there was no data available for immunomodulators and combination therapies for this outcome...Conclusion On network meta-analysis immunomodulators and advanced therapies for maintenance phase, combination of anti-TNFs and immunomodulators followed by anti-TNF monotherapy had large effect size with moderate certainty for prevention of clinical relapse. There was moderate to high certainty evidence to suggest newer advanced therapies are effective in prevention of loss of clinical response.
- ORAL SMALL MOLECULES ARE NOT ASSOCIATED WITH INCREASED CANCER RATES IN IBD PATIENTS (Ballroom B - Walter E. Washington Convention Center) - Mar 14, 2024 - Abstract #DDW2024DDW_4645;
Importantly, there was not an increase in malignancies in older IBD patients treated with OSM. While further studies and longer follow up periods are needed to validate these findings, our results provide reassurance regarding the safety of OSM in IBD.
- BIOLOGICS AND JAK INHIBITORS DECREASE MAJOR CARDIOVASCULAR EVENTS (MACE) IN IBD PATIENTS. DATA FROM A LARGE NATIONAL COHORT. IS IT THE MECHANISM OF THE DRUG OR CONTROL OF DISEASE? (Ballroom B - Walter E. Washington Convention Center) - Mar 14, 2024 - Abstract #DDW2024DDW_4643;
IBD patients treated with biologics and JAK inhibitors are less likely to have MACE with the most notable risk reduction seen with anti-TNF medications after adjusting for CV risk factors. Studies are needed to see whether this decrease in risk is due to control of the disease or mechanism of a drug.
- Rinvoq (upadacitinib) / AbbVie
PHARMACOLOGIC ANTICOAGULATION IS PROTECTIVE AGAINST RECURRENT VENOUS THROMBOEMBOLIC EVENTS ASSOCIATED WITH JANUS KINASE INHIBITOR USE IN PATIENTS WITH PRIOR THROMBOSIS (Ballroom B - Walter E. Washington Convention Center) - Mar 14, 2024 - Abstract #DDW2024DDW_4642;
However, we also found that concurrent AC appears protective in at-risk patients on a JAKi. If supported, this may enable JAKi use in these patients.
- tofacitinib / Generic mfg.
PREGNANCY OUTCOMES AFTER MATERNAL OR PATERNAL EXPOSURE IN THE TOFACITINIB ULCERATIVE COLITIS CLINICAL PROGRAM (Ballroom B - Walter E. Washington Convention Center) - Mar 14, 2024 - Abstract #DDW2024DDW_4641;
P2, P3, P3
6,7 Limitations included the low number of reported pregnancies and available follow-up. Tofacitinib should not be used during pregnancy unless necessary.
- tofacitinib / Generic mfg.
4280: IBD Adverse Events Related to Therapy: Focus on Small Molecules (Ballroom B - Walter E. Washington Convention Center) - Mar 14, 2024 - Abstract #DDW2024DDW_4640;
The effect of other therapies on IBD, including GLP1 agonists and PPI's are also examined. Learning Objectives: Describe pregnancy outcomes after maternal or paternal exposure to tofacitinib, Determine the effect of small molecules on cardiovascular risk in IBD, Assess the safety and effectiveness of GLP-1 agonists in IBD
- Litfulo (ritlecitinib) / Pfizer, Rinvoq (upadacitinib) / AbbVie
NOVEL PLATFORMS FOR IDENTIFYING AND TESTING SMALL MOLECULE DRUG BASED TREATMENTS FOR INFLAMMATORY BOWEL DISEASE. (140AB - Walter E. Washington Convention Center) - Mar 14, 2024 - Abstract #DDW2024DDW_4231;
We identified immune features of JAKi across multiple cell types and signaling pathways toward a deeper understanding of their function. There were differential response signatures of UC and CD to JAKi.
- Jyseleca (filgotinib) / Galapagos, Gilead, SOBI
FILGOTINIB IN ULCERATIVE COLITIS: EARLY REAL-WORLD MULTICENTRE UK EXPERIENCE (Hall A, Poster Hall - Walter E. Washington Convention Center) - Mar 14, 2024 - Abstract #DDW2024DDW_3285;
There were differential response signatures of UC and CD to JAKi. 77 (36%) patients were na
- Rinvoq (upadacitinib) / AbbVie, Jyseleca (filgotinib) / Galapagos, Gilead, SOBI
EXPLORING THE IMPACT OF JAK INHIBITORS ON TOTAL CHOLESTEROL LEVELS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: A REAL-WORLD DATA ANALYSIS (Hall A, Poster Hall - Walter E. Washington Convention Center) - Mar 14, 2024 - Abstract #DDW2024DDW_3278;
Gaining insights into the interplay between JAK inhibitors and lipid metabolism within the realm of IBD treatment is essential for enhancing patient care and proactively addressing potential cardiovascular risks linked to these therapeutic interventions. 1.Herrera-deGuise C, Serra-Ruiz X, Lastiri E and Borruel N (2023) JAK inhibitors: A new dawn for oral therapies in inflammatory bowel diseases.
- Omvoh (mirikizumab) / Eli Lilly
EFFECT OF MIRIKIZUMAB ON CLINICAL AND ENDOSCOPIC OUTCOMES AFTER 1 ANTI-TNF FAILURE IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (Hall A, Poster Hall - Walter E. Washington Convention Center) - Mar 14, 2024 - Abstract #DDW2024DDW_3276;
P3
At the LUCENT-1 induction baseline, 41% of the population had experienced a biologic/tofacitinib failure, and 36.3% experienced at least one anti-TNF failure. Mirikizumab is efficacious for induction and maintenance therapy in patients with moderately to severely active UC who have failed one prior anti-TNF.
- tofacitinib / Generic mfg.
POST-MARKETING SURVEILLANCE OF TOFACITINIB IN PATIENTS WITH ULCERATIVE COLITIS IN JAPAN: A FINAL REPORT OF SAFETY AND EFFECTIVENESS DATA (Hall A, Poster Hall - Walter E. Washington Convention Center) - Mar 14, 2024 - Abstract #DDW2024DDW_3253;
2 However, rates of HZ were higher in this final analysis than in the tofacitinib UC clinical program. 2 Tofacitinib was effective in Japanese pts with UC in a clinical practice setting.
- PATIENTS IN TRIALS OF MODERATE-TO-SEVERE UC WHO ARE EXPOSED TO PLACEBO ARE MORE LIKELY TO SUFFER HARM THAN THOSE RECEIVING ACTIVE TREATMENT: THE LACK OF CLINICAL EQUIPOISE IN TRADITIONAL STUDY DESIGNS (Hall A, Poster Hall - Walter E. Washington Convention Center) - Mar 14, 2024 - Abstract #DDW2024DDW_3207;
Induction treatment responders re-randomized for maintenance to PBO experienced greater harms (lower NNH) than treat-through PBO patients. These findings raise concern about clinical equipoise in PBO-controlled trials of moderate-to-severe UC and support ongoing efforts to design trials with active comparator arms and adaptive or platform methodologies.
- Remicade (infliximab) / J&J
LIVER INJURY FROM MEDICATIONS USED FOR TREATING INFLAMMATORY BOWEL DISEASE: THE DRUG-INDUCED LIVER INJURY NETWORK EXPERIENCE (Hall A, Poster Hall - Walter E. Washington Convention Center) - Mar 14, 2024 - Abstract #DDW2024DDW_3136;
Agents commonly used to treat IBD are associated with DILI and represent 1 in 20 prospectively enrolled cases in DILIN. Clinical features of liver injury including latency, injury pattern, bilirubin and dermatologic features may help in distinguishing implicated agents and informing prognosis in patients with IBD and suspected DILI.
- Rinvoq (upadacitinib) / AbbVie
ONE-YEAR COMPARATIVE EFFECTIVENESS OF UPADACITINIB VERSUS TOFACITINIB FOR ULCERATIVE COLITIS: A MULTICENTER COHORT STUDY (146AB - Walter E. Washington Convention Center) - Mar 14, 2024 - Abstract #DDW2024DDW_2194;
AEs were consistent with known safety profiles. These findings should be confirmed prospectively.
- tofacitinib / Generic mfg.
COMBINATION THERAPY OF THE FXR AGONIST FXR314 WITH TOFACITINIB IN MODELS OF INFLAMMATORY BOWEL DISEASE (Hall A, Poster Hall - Walter E. Washington Convention Center) - Mar 14, 2024 - Abstract #DDW2024DDW_1298;
When administered at sub-efficacious doses, FXR314 and tofacitinib synergistically improved colitis, similar to the effects seen with each agent alone at optimal dose levels. In conclusion, this study, demonstrates the synergistic potential of combining the non-bile acid FXR agonist FXR314 with the JAK inhibitor tofacitinib, supporting the notion of FXR314 as both a monotherapy and a combination therapy in IBD.
- CHARACTERIZING PRACTICE PATTERNS IN DISEASE ACTIVITY MONITORING OF INFLAMMATORY BOWEL DISEASE PATIENTS FOLLOWING BIOLOGIC INITIATION WITHIN A LARGE REGIONAL HEALTHCARE SYSTEM (Hall A, Poster Hall - Walter E. Washington Convention Center) - Mar 14, 2024 - Abstract #DDW2024DDW_1186;
Symptomatic patients completed endoscopy at nearly triple the rate of asymptomatic patients, suggesting deferral of short-term diagnostic endoscopy for asymptomatic patients. Subsequent research should include further subgroup analyses, assess variation in IBD outcomes between patients completing TTT versus routine care, and consider explanations for limited uptake of TTT for endoscopy and biomarkers.
- PARADOXICAL RISK OF RHEUMATOID ARTHRITIS IN INFLAMMATORY BOWEL DISEASE PATIENTS EXPOSED TO TUMOR NECROSIS FACTOR INHIBITORS: A PROPENSITY MATCHED MULTI-NETWORK STUDY (Hall A, Poster Hall - Walter E. Washington Convention Center) - Mar 14, 2024 - Abstract #DDW2024DDW_1155;
Conclusion In this large retrospective case-control study among IBD patients, we did not detect an association between anti-TNF therapy and paradoxical increased risk of RA when compared to IBD patients who received non-anti-TNF advanced and non-advanced IBD therapy. Our results are consistent with TNF-?'s role as a major proinflammatory cytokine and subsequent modulation of systemic inflammation by anti-TNF medications.
- Rinvoq (upadacitinib) / AbbVie
INCREASED RISK OF ACUTE VENOUS THROMBOEMBOLISM WITH UPADACITINIB COMPARED TO TOFACITINIB DURING INITIAL PERIOD OF JANUS KINASE INHIBITOR EFFICACY ASSESSMENT (Hall A, Poster Hall - Walter E. Washington Convention Center) - Mar 14, 2024 - Abstract #DDW2024DDW_1152;
These results suggest that upadacitinib may possess an increased and more rapid VTE risk compared to tofacitinib and lead to earlier VTEs in at-risk patients. Our findings suggest that tofacitinib may be a safer option while evaluating early JAKi efficacy during the first critical weeks of therapy.
- tofacitinib / Generic mfg.
INTRAOPERATIVE AND POSTOPERATIVE OUTCOMES IN TOFACITINIB-TREATED ACUTE SEVERE ULCERATIVE COLITIS PATIENTS UNDERGOING TOTAL ABDOMINAL COLECTOMY (Hall A, Poster Hall - Walter E. Washington Convention Center) - Mar 14, 2024 - Abstract #DDW2024DDW_1145;
Additional details on patient demographics and disease course are presented in Table 1. Two (6.3%) patients in the tofacitinib-treated group compared to four (11.8%) patients in in the control group developed at least one grade 3 postoperative complication (p=0.4431).
- BIOLOGICS AND ORAL SMALL MOLECULES ARE NOT ASSOCIATED WITH INCREASED MAJOR ADVERSE CARDIOVASCULAR EVENTS OR VENOUS THROMBOEMBOLISM IN OLDER IBD PATIENTS (Hall A, Poster Hall - Walter E. Washington Convention Center) - Mar 14, 2024 - Abstract #DDW2024DDW_1144;
Older IBD patients treated with biologics or OSM were not at increased risk of MACE or VTE. While further studies and longer follow up periods are needed to confirm these findings, our results provide reassurance regarding the safety of these medications in IBD.
- Humira (adalimumab) / AbbVie
A HUMAN PRIMARY CELL MODEL OF THE INFLAMED COLON WITH UTILITY FOR IBD THERAPEUTIC DRUG DISCOVERY AND DEVELOPMENT. (Hall A, Poster Hall - Walter E. Washington Convention Center) - Mar 14, 2024 - Abstract #DDW2024DDW_876;
antibody) and tofacitinib (STAT inhibitor). Together, these data highlight the ability to use RepliGut
- Stelara (ustekinumab) / J&J, Entyvio (vedolizumab) / Takeda, Humira (adalimumab) / AbbVie
PROACTIVE PATIENT ENGAGEMENT TO PROMOTE REPRESENTATIVE PATIENT POPULATIONS FOR FUTURE TRIALS OF DUAL TARGETED THERAPIES IN INFLAMMATORY BOWEL DISEASES (Hall A, Poster Hall - Walter E. Washington Convention Center) - Mar 14, 2024 - Abstract #DDW2024DDW_714;
P4
ExiGem (NCT06095128) is a phase 4, open-label, single-arm study to evaluate the induction of response and remission following treatment with vedolizumab and tofacitinib in patients with moderate to severe UC...Conclusion Here we describe the study designs for the novel EXPLORER 2.0 and ExiGem trials of combined targeted IBD therapies. By proactively engaging patients to gain insights on barriers to enrollment we identified opportunities to improve the study designs to optimize patient recruitment.
- tofacitinib / Generic mfg.
PUBLICLY INSURED PATIENTS WITH IBD, INCLUDING THOSE WITH SEVERE DISEASE, ARE MORE LIKELY TO RECEIVE STEROIDS AND LESS LIKELY TO BE TREATED WITH ADVANCED THERAPIES THAN PRIVATELY INSURED PATIENTS (Hall A, Poster Hall - Walter E. Washington Convention Center) - Mar 14, 2024 - Abstract #DDW2024DDW_705;
Prior studies using large claims databases often consider biologic use a surrogate for severe disease; our data would suggest this underestimates the proportion of publicly insured patients with severe disease. This study provides real-world evidence of insurance disparities in severe IBD patients using validated metrics for disease severity and supports the re-evaluation of access to steroid-sparing therapies for publicly insured patients.
- Remicade (infliximab) / J&J, Skyrizi (risankizumab-rzaa) / AbbVie, Boehringer Ingelheim, Rinvoq (upadacitinib) / AbbVie
INTERVALS OF A PLANT-BASED, LOW-CALORIE DIET IMPROVE CLINICAL SYMPTOMS COMPARED WITH USUAL DIET IN PATIENTS INITIATING ADVANCED THERAPIES FOR MODERATE-TO-SEVERE ULCERATIVE COLITIS (146C - Walter E. Washington Convention Center) - Mar 14, 2024 - Abstract #DDW2024DDW_87;
Our pilot study indicates that intermittent low-calorie, PB diets may enhance response to induction medical therapy among patients with active UC. It also suggests that even short, defined intervals of diet therapy may provide benefit in UC.
- | tofacitinib / Generic mfg.
Journal: Effectiveness Of Tofacitinib In Ulcerative Colitis Patients: A Nationwide Veterans Administration Cohort study. (Pubmed Central) - Mar 14, 2024
It also suggests that even short, defined intervals of diet therapy may provide benefit in UC. In a nationwide cohort of UC patients initiating tofacitinib, effectiveness was seen in half of the elderly patients.
- | tofacitinib / Generic mfg.
Journal: Risk of Venous Thromboembolism with Tofacitinib Versus Tumor Necrosis Factor Inhibitors in Cardiovascular Risk-enriched Rheumatoid Arthritis Patients. (Pubmed Central) - Mar 14, 2024
Across treatments, VTE risk factors were aligned with previous studies in the general RA population. These data highlight the importance of assessing VTE risk factors, including age, BMI, and VTE history, when considering initiation of tofacitinib or TNFi in patients with active RA.
- | tofacitinib / Generic mfg.
Journal: Coccidioides Serologic Screening Practices in Individuals With Rheumatic and Autoimmune Diseases. (Pubmed Central) - Mar 13, 2024
Coccidioides serologic screening rates among Medicare beneficiaries with rheumatic/autoimmune diseases on b/tsDMARDs, csDMARDs, and noninhaled corticosteroids was low in Coccidioides spp.-US endemic regions between 2012 and 2016. Alignment of screening recommendations and clinical practice is needed.
- | tofacitinib / Generic mfg.
Journal, IO biomarker: Effect of tofacitinib on the phenotype and activity of Caco?2 cells in a model of inflammatory bowel disease. (Pubmed Central) - Mar 13, 2024
The addition of tofacitinib decreased the activity of the examined parameters of oxidative and apoptotic stress, while increasing the activity of the parameter examined to evaluate the degree of intercellular connections. In conclusion, the inhibitory effects of tofacitinib on oxidative stress, as well as its anti-apoptotic and regenerative effects, provide important information regarding the positive effect of tofacitinib on Caco-2 cells, and therefore constitute potential information about the beneficial effect of the evaluated drug in UC.
- |||| tofacitinib / Generic mfg.
New P4 trial: Tofacitinib in the Treatment of Refractory Axial Spondyloarthritis Patients: A Dose Escalation Study (clinicaltrials.gov) - Mar 12, 2024
P4, N=92, Completed, Sponsor: Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
- || Olumiant (baricitinib) / Incyte, Eli Lilly, Scenesse (afamelanotide) / Clinuvel, Amevive (alefacept) / Astellas
Review, Journal: A systematic review of case series and clinical trials investigating systemic oral or injectable therapies for the treatment of vitiligo. (Pubmed Central) - Mar 12, 2024
OMP, Methotrexate, Azathioprine, Cyclosporine, Mycophenolate mofetil, Simvastatin, Apremilast, Minocycline, Afamelanotide, Tofacitinib, Baricitinib, Antioxidants, and oral/injectable corticosteroids are effective treatment methods. However, oral zinc and alefacept did not show effectiveness.
- | Rinvoq (upadacitinib) / AbbVie
Journal, HEOR: One-Year Comparative Effectiveness of Upadacitinib Versus Tofacitinib For Ulcerative Colitis: A Multicenter Cohort Study. (Pubmed Central) - Mar 12, 2024
However, oral zinc and alefacept did not show effectiveness. Upadacitinib was more effective at achieving SFCR in UC at 52 weeks versus tofacitinib.
- | tofacitinib / Generic mfg.
Journal: Tofacitinib ameliorates skin inflammation in a case of severe autosomal recessive congenital ichthyosis. (Pubmed Central) - Mar 12, 2024
Moreover, TGM1 distribution was normalized although enzymatic activity remained deficient. This study suggests that oral tofacitinib may be a useful therapy to consider in patients with ARCI.
- Rinvoq (upadacitinib) / AbbVie
Identification of intestinally restricted imidazo-pyrrolopyridines for the treatment of IBD (In-person; Room 356 (Ernest N. Morial Convention Center)) - Mar 12, 2024 - Abstract #ACSSp2024ACS_Sp_6590;
We explored a class of imidazo-pyrrolopyridines to build an understanding of the physicochemical properties that drive intestinal tissue targeting in vivo , and in a preclinical model we demonstrate dose-dependent inhibition of STAT phosphorylation in colonic tissue post oral dosing with no significant systemic pharmacodynamic activity. The medicinal chemistry approach to achieve this profile and key learnings will be discussed.
- | tofacitinib / Generic mfg.
New trial, Stroma: Methotrexate Combined With Tofacitinib in Rheumatoid Arthritis (clinicaltrials.gov) - Mar 12, 2024
P=N/A, N=130, Not yet recruiting, Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
- || tofacitinib / Generic mfg.
Review, Journal: Successful Treatment of Erosive Lichen Planus With Tofacitinib: A Case Series and Review of the Literature. (Pubmed Central) - Mar 11, 2024
These patients were then treated with 10 mg of tofacitinib per day. Interestingly, with the new treatment, the patients' mean overall satisfaction score was 9.16 out of 10 (range: 8-10), the mean pain relief score was 9.16 out of 10 (range: 9-10) and patients' symptom improvement also began an average of 1.33 months after starting treatment (range: 1-2.5 months).
- | tofacitinib / Generic mfg.
Journal: Tofacitinib use in ulcerative colitis: An expert consensus for day-to-day clinical practice. (Pubmed Central) - Mar 11, 2024
Maternal exposure to tofacitinib should be avoided during pre-conception, pregnancy, and lactation. There is emerging evidence of tofacitinib in acute severe colitis, although the exact positioning (first-line with steroids or second-line) is uncertain.
- || Review, Journal: Application of JAK inhibitors in paradoxical reaction through immune-related dermatoses. (Pubmed Central) - Mar 10, 2024
This article focuses on JAK inhibitors such as tofacitinib, baricitinib, ruxolitinib, Abrocitinib, upadacitinib, and deucravacitinib, to explore the possible application in treatment of paradoxical reactions. Common side effects, baseline risk factors and safety use of JAK inhibitors were discussed.
- | tofacitinib / Generic mfg.
Journal, HEOR, Real-world evidence, Real-world: Real-world evaluation of persistence, effectiveness and usage patterns of tofacitinib in treatment of psoriatic arthritis in Australia. (Pubmed Central) - Mar 9, 2024
Overall, treatment persistence was similar for tofacitinib, IL-17Ai and TNFi, but tofacitinib exhibited longer persistence than TNFi in a matched population. Key Points
- Cost-Effectiveness Analysis of Biologics Used for the Treatment of Ankylosing Spondylitis in China () - Mar 8, 2024 - Abstract #ISPOR2024ISPOR_2208;
Overall, Secukinumab had the most cost-effective advantage, followed by Ixekizumab, which were both IL-17 inhibitors. Different pricing of a biologic by different manufacturers can greatly affect the economics.
- Price Trends and Analysis of Targeted Immunomodulatory (TIM) Disease-Modifying Antirheumatic Drugs for Rheumatoid Arthritis Therapy () - Mar 8, 2024 - Abstract #ISPOR2024ISPOR_2206;
Different pricing of a biologic by different manufacturers can greatly affect the economics. All timDMARDs
- Zymfentra (infliximab-dyyb subcutaneous) / Celltrion
Budget Impact of Infliximab Subcutaneous from the US Healthcare Perspective () - Mar 8, 2024 - Abstract #ISPOR2024ISPOR_2202;
Infliximab is considered as a potent treatment compared to the recently developed biologics. The model, based on the assumption that analyzed molecules have similar efficacy, suggests that treatment with Zymfentra will yield cost savings while improving patient convenience and offering intangible benefits.
- Humira (adalimumab) / AbbVie
Medication Adherence, Persistence, and Treatment Switching in Patients Receiving Advanced Therapies for Rheumatoid Arthritis in Clinical Practice () - Mar 8, 2024 - Abstract #ISPOR2024ISPOR_2151;
Adult patients diagnosed with RA, initiating an AT (index; date of first pharmacy claim for upadacitinib, tofacitinib, baricitinib, adalimumab, etanercept, abatacept, or tocilizumab) with recent TNFi experience (?12 months pre-index), and with continuous insurance enrollment for ?12 months pre- and post-index were included. Overall, treatment adherence was significantly higher, and rates of treatment discontinuation or switching were significantly lower for patients initiating upadacitinib compared with other ATs after recent TNFi treatment.
- Olumiant (baricitinib) / Incyte, Eli Lilly
Risk of Venous Thromboembolism with Janus Kinase Inhibitors in Rheumatoid Arthritis: A Systematic Review () - Mar 8, 2024 - Abstract #ISPOR2024ISPOR_2127;
The systemic review found mixed evidence regarding the risk of VTE with JAKi as compared to TNFi, and the JAKi class-specific VTE risk as compared to TNFi in RA was also unclear. However, there was variation in the risk of VTE with individual JAKi vs. TNFi.
- Enbrel (etanercept) / Pfizer, Amgen, Humira (adalimumab) / AbbVie, Rituxan (rituximab) / Roche
Treatment Regimens and Persistence in Colombian Patients Diagnosed With Rheumatologic Diseases After Failure of Conventional Disease-Modifying Antirheumatic Drugs () - Mar 8, 2024 - Abstract #ISPOR2024ISPOR_2107;
These patients underwent few medications switching after starting the first biological DMARD; however, a quarter interrupted or discontinued the therapy. Combination therapy with conventional DMARDs decrease probability of switching.
- Clinical and Health Outcomes Associated With Different Treatment Sequences for Moderate-to-Severe Ulcerative Colitis () - Mar 8, 2024 - Abstract #ISPOR2024ISPOR_1945;
The model simulated ozanimod being added to current 1L TNFi basket of infliximab and adalimumab or replacing the 1L biologics basket of infliximab, adalimumab, vedolizumab, and/or ustekinumab... Primarily driven by efficacy and safety, these results suggest that positioning ozanimod early in UC treatment may lead to improvements in ToT and better clinical outcomes with minimal impact on costs.